Arteriovenous Access for Continuous Dialysis in Critically Ill Patients
This study is looking at whether patients who are critically ill and need continuous dialysis (Continuous Renal Replacement Therapy or CRRT) can safely use their existing permanent dialysis access (an arteriovenous fistula or graft). Currently, these patients often need a temporary tube (central venous catheter) placed in a large vein. About 50 patients will participate. Researchers will check how well the permanent access works for CRRT and if there are any problems, like infections or bleeding. The main goal is to see if using your existing dialysis access is a safe and practical option, which could help avoid the risks associated with temporary catheters. This study focuses on patients with End Stage Kidney Disease (ESKD) who have been on hemodialysis for over a year.
- Study design
- This is a single-arm study, meaning all participants will receive the intervention. About 50 patients will be enrolled.
- What's involved
- You would receive continuous renal replacement therapy (CRRT) using your existing arteriovenous access. Your care would involve continuous monitoring by ICU nursing staff and support from dialysis nurses for placing and removing needles.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will monitor for complications from the start of CRRT until it stops, ICU discharge, or 7 days after CRRT (whichever comes first), and then again 30 days after CRRT through chart review.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Prospective Analysis of Arteriovenous Access (AVA) Use in Continuous Renal Replacement Therapy: A Feasibility Project
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Armando F Rodriguez Lopez, MD · PRINCIPAL_INVESTIGATOR · ECU Health Medical Center
- Iskra Myers, MD · STUDY_DIRECTOR · ECU Health Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Technical Feasibility of using Arteriovenous Access for CRRT deliveryFrom initiation of CRRT until discontinuation of CRRT, ICU discharge or 7 days post-CRRT (whichever occurs first), and 30 days post-CRRT via chart review.
AVA viability upon discontinuation of the first CRRT run. AVA viability will be determined by functional access for subsequent dialysis, confirmed within 24-48 hours after discontinuation of the first CRRT run by the presence of a thrill and/or bruit on physical examination and post-CRRT flow studies showing less than a 25% reduction from baseline
- Access-related serious complicationsFrom initiation of CRRT until discontinuation of CRRT, ICU discharge or 7 days post-CRRT (whichever occurs first), and 30 days post-CRRT via chart review.
Serious complications will include any of the following: major bleeding event, needle dislodgement with hemodynamic compromise, access thrombosis requiring intervention, death related to AVA complications, acute limb ischemia related to AVA or permanent loss of AVA function attributable to study participation.